A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
MK-2140-002
Phase 2 Terminated
102 enrolled 36 charts
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Phase 1 Terminated
44 enrolled
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
AM-003
Phase 1 Terminated
5 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
LODESTAR
Phase 2 Terminated
83 enrolled 16 charts
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 29 charts
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Phase 1/2 Terminated
2 enrolled 9 charts
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Phase 1 Terminated
60 enrolled
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Phase 1 Terminated
16 enrolled
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
Phase 1 Terminated
9 enrolled
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Phase 1 Terminated
6 enrolled
The Natural History of Solid Organ Cancer Stem Cells (SOCSC)
Terminated
190 enrolled
PembroMab
Phase 1/2 Terminated
16 enrolled 6 charts
N1
Terminated
23 enrolled
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Phase 1/2 Terminated
5 enrolled
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Phase 1 Terminated
54 enrolled
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Phase 1 Terminated
60 enrolled
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
Terminated
200 enrolled
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Phase 1 Terminated
14 enrolled
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
Phase 1 Terminated
24 enrolled